US 11,970,452 B2
Modulators of mas-related G-protein receptor X2 and related products and methods
Marion Lanier, San Diego, CA (US); Marcus Boehm, San Diego, CA (US); Liming Huang, San Diego, CA (US); Esther Martinborough, San Diego, CA (US); Marcos Sainz, San Diego, CA (US); Brandon Selfridge, San Diego, CA (US); and Adam Yeager, San Diego, CA (US)
Assigned to Escient Pharmaceuticals, Inc., San Diego, CA (US)
Filed by Escient Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Oct. 20, 2021, as Appl. No. 17/506,447.
Claims priority of provisional application 63/094,864, filed on Oct. 21, 2020.
Prior Publication US 2022/0177434 A1, Jun. 9, 2022
Int. Cl. C07D 215/44 (2006.01); C07D 239/94 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)
CPC C07D 215/44 (2013.01) [C07D 239/94 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01)] 4 Claims
 
1. A compound having formula (TB):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein:
R1b is phenyl substituted with Rq;
each R is independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or alkylamino;
Rq is —N(R)C(O)R or —N(R)S(O)2R;
R2 is H;
R3 is H;
R4 is H or Cl;
R5 is H;
R6 is CF3;
each Rx is H;
W is N;
Z is CRz; and
Rz is H.